Download PDF
Z Gastroenterol 2006; 44(1): 57-66
DOI: 10.1055/s-2005-858989
Übersicht

© Karl Demeter Verlag im Georg Thieme Verlag KG Stuttgart · New York

TGF-β/Smad Signaling in the Injured Liver

TGF-β/Smad Signalwege in der geschädigten LeberK. Breitkopf1 , P. Godoy1 , L. Ciuclan1 , M. V. Singer1 , S. Dooley1
  • 1Department of Medicine II, Division of Molecular Alcohol Research in Gastroenterology, University Hospital of Heidelberg at Mannheim
Further Information

Publication History

Manuskript eingetroffen: 12.12.2005

Manuskript akzeptiert: 12.12.2005

Publication Date:
05 January 2006 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Direkte und indirekte Wirkmechanismen des Wachstumsfaktors TGF-β stehen im Zentrum fibrotischer Umbauprozesse in der geschädigten Leber. TGF-β aktiviert hepatische Sternzellen (HSCs), die daraufhin zu matrixsynthetisierenden Myofibroblasten transdifferenzieren. Gleichzeitig induziert TGF-β Apoptose und trägt damit zum Untergang des Leberparenchyms bei. Weiter ist TGF-β wichtig für die Wachstumskontrolle proliferierender Hepatozyten während regenerativer Prozesse. Das bedeutet, dass der gesamte durch TGF-β regulierte Wundheilungsprozess in der geschädigten Leber aus einem komplexen Netzwerk intrazellulärer und interzellulärer Interaktionen der verschiedenen Leberzelltypen resultiert. In der hier vorliegenden Übersicht wird der aktuelle Wissensstand der TGF-β-Signaltransduktion in hepatischen Sternzellen mit besonderem Augenmerk auf die Smad-vermittelten Signalwege dargestellt. Darüber hinaus wird das molekulare Zusammenspiel zwischen profibrogenen TGF-β-Effekten und antifibrogenen, durch IFN-γ ausgelösten Wegen beschrieben. Schließlich wird die Plastizität von Hepatozyten und deren epithelial-mesenchymale Transdifferenzierung im Rahmen der Fibrogenese und Hepatokarzinogenese diskutiert, wobei auch hier insbesondere die Rolle des TGF-β zentralisiert wird.

Abstract

TGF-β, acting both directly and indirectly, represents a central mediator of fibrogenic remodeling processes in the liver. Besides hepatic stellate cells (HSCs), which are induced by TGF-β to transdifferentiate to myofibroblasts and to produce extracellular matrix, hepatocytes are also strongly responsive for this cytokine, which induces apoptosis during fibrogenesis and provides growth control in regeneration processes. Based on this, TGF-β-mediated hepatic responses to injury are the result of a complex interplay between the different liver cell types. In this review we summarize the knowledge about TGF-β signal transduction in HSCs with special impact on Smad pathways. We further describe a molecular cross-talk between profibrogenic TGF-β and antifibrogenic IFN-γ signaling in liver cells. Finally, we introduce hepatocyte plasticity and epithelial-to-mesenchymal transition in the liver, which is well established in tumorigenesis, as a potential feature of fibrogenesis and highlight possible action points of TGF-β in these contexts.

Schlüsselwörter

TGF-β - Smad - Leber - Fibrose - HSC - EMT - Interferon-γ

Key words

TGF-β - Smad - liver - fibrosis - HSC - EMT - interferon-γ

References

  • 1 Bissell D M, Roulot D, George J. Transforming growth factor beta and the liver.  Hepatology. 2001;  44 859-867
    PubMedGoogle Scholar
  • 2 Sporn M B, Roberts A B, Wakefield L M. Some recent advances in the chemistry and biology and transforming growth factor beta.  J Cell Biol. 1987;  44 1039-1045
    PubMedGoogle Scholar
  • 3 Massague J. The transforming growth factor-beta family.  Anne Rev Cell Biol. 1990;  44 597-641
    PubMedGoogle Scholar
  • 4 Sanford L P, Ormsby I, de Gittenberger-Groot A C. et al . TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes.  Development. 1997;  44 2659-2670
    PubMedGoogle Scholar
  • 5 Shull M M, Ormsby I, Kier A B. et al . Targeted disruption of the mouse transforming growth factor beta-1 gene results in multifocal inflammatory disease.  Nature. 1992;  44 693-699
    PubMedGoogle Scholar
  • 6 Kulkarni A B, Huh C G, Becker D. et al . Transforming growth factor beta-1 null mutation in mice causes excessive inflammatory response and early death.  Proc Natl Acad Sci USA. 1993;  44 770-774
    PubMedGoogle Scholar
  • 7 Diebold R J, Eis M J, Yin M. et al . Early-onset multifocal inflammation in the transforming growth factor beta 1-null mouse is lymphocyte mediated.  Proc Natl Acad Sci USA. 1995;  44 12 215-12 219
    PubMedGoogle Scholar
  • 8 Proetzel G, Pawlowski S A, Wiles M V. et al . Transforming growth factor-beta 3 is required for secondary palate fusion.  Nat Genet. 1995;  44 409-414
    PubMedGoogle Scholar
  • 9 Kaartinen V, Voncken J W, Shuler C. et al . Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction.  Nat Genet. 1995;  44 415-421
    PubMedGoogle Scholar
  • 10 Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus.  Cell. 2003;  44 685-700
    PubMedGoogle Scholar
  • 11 Miyazono K. TGF-beta receptors and signal transduction.  Int J Hematol. 1997;  44 97-104
    PubMedGoogle Scholar
  • 12 Wickert L, Abiaka M, Bolkenius U. et al . Corticosteroids stimulate selectively transforming growth factor (TGF)-beta receptor type III expression in transdifferentiating hepatic stellate cells.  J Hepatol. 2004;  44 69-76
    PubMedGoogle Scholar
  • 13 Meurer S K, Tihaa L, Lahme B. et al . Identification of endoglin in rat hepatic stellate cells: new insights into TGF-beta receptor signaling.  J Biol Chem. 2004;  44 3078-3087
    PubMedGoogle Scholar
  • 14 Hayashi H, Abdollah S, Qiu Y. et al . The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling.  Cell. 1997;  44 1165-1173
    PubMedGoogle Scholar
  • 15 Nakao A, Afrakhte M, Moren A. et al . Identification of Smad7, a TGF beta-inducible antagonist of TGF-beta signalling.  Nature. 1997;  44 631-635
    PubMedGoogle Scholar
  • 16 Stopa M, Benes V, Ansorge W. et al . Genomic locus and promoter region of rat Smad7, an important antagonist of TGFbeta signaling.  Mamm Genome. 2000;  44 169-176
    PubMedGoogle Scholar
  • 17 Luo K. Ski and SnoN: negative regulators of TGF-beta signaling.  Curr Opin Genet Dev. 2004;  44 65-70
    PubMedGoogle Scholar
  • 18 Macias-Silva M, Li W, Leu J I. et al . Up-regulated transcriptional repressors SnoN and Ski bind Smad proteins to antagonize transforming growth factor-beta signals during liver regeneration.  J Biol Chem. 2002;  44 28 483-28 490
    PubMedGoogle Scholar
  • 19 Moustakas A, Heldin C H. Non-Smad TGF-beta signals.  J Cell Sci. 2005;  44 3573-3584
    PubMedGoogle Scholar
  • 20 Gressner A M, Weiskirchen R, Breitkopf K. et al . Roles of TGF-beta in hepatic fibrosis.  Front Biosci. 2002;  44 d793-807
    PubMedGoogle Scholar
  • 21 Breitkopf K HS, Wiercinska E, Singer M V. et al . Anti-TGF-beta strategies for the treatment of chronic liver disease.  ACER. in press; 
    PubMedGoogle Scholar
  • 22 Bissell D M, Wang S S, Jarnagin W R. et al . Cell-specific expression of transforming growth factor-beta in rat liver - Evidence for autocrine regulation of hepatocyte proliferation.  J Clin Invest. 1995;  44 447-455
    PubMedGoogle Scholar
  • 23 Dooley S, Hamzavi J, Breitkopf K. et al . Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats.  Gastroenterology. 2003;  44 178-191
    PubMedGoogle Scholar
  • 24 Ueberham E, Low R, Ueberham U. et al . Conditional tetracycline-regulated expression of TGF-beta1 in liver of transgenic mice leads to reversible intermediary fibrosis.  Hepatology. 2003;  44 1067-1078
    PubMedGoogle Scholar
  • 25 Sanderson N, Factor V, Nagy P. et al . Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions.  Proc Natl Acad Sci USA. 1995;  44 2572-2576
    PubMedGoogle Scholar
  • 26 Kanzler S, Lohse A W, Keil A. et al . TGF-beta 1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis.  Amer J Physiol-Gastrointest L. 1999;  44 G1059-G1068
    PubMedGoogle Scholar
  • 27 Qi Z, Atsuchi N, Ooshima A. et al . Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat.  Proc Nat Acad Sci USA. 1999;  44 2345-2349
    PubMedGoogle Scholar
  • 28 Ueno H, Sakamoto T, Nakamura T. et al . A soluble transforming growth factor beta receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats.  Hum Gene Ther. 2000;  44 33-42
    PubMedGoogle Scholar
  • 29 George J, Roulot D, Koteliansky V E. et al . In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: A potential new therapy for hepatic fibrosis.  Proc Nat Acad Sci USA. 1999;  44 12 719-12 724
    PubMedGoogle Scholar
  • 30 Dooley S, Delvoux B, Lahme B. et al . Modulation of transforming growth factor beta response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts.  Hepatology. 2000;  44 1094-1106
    PubMedGoogle Scholar
  • 31 Dooley S, Streckert M, Delvoux B. et al . Expression of Smads during in vitro transdifferentiation of hepatic stellate cells to myofibroblasts.  Biochem Biophys Res Commun. 2001;  44 554-562
    PubMedGoogle Scholar
  • 32 Dooley S, Delvoux B, Streckert M. et al . Transforming growth factor beta signal transduction in hepatic stellate cells via Smad2/3 phosphorylation, a pathway that is abrogated during in vitro progression to myofibroblasts. TGFbeta signal transduction during transdifferentiation of hepatic stellate cells.  FEBS Lett. 2001;  44 4-10
    PubMedGoogle Scholar
  • 33 Roulot D, Sevcsik A M, Coste T. et al . Role of transforming growth factor beta type II receptor in hepatic fibrosis: studies of human chronic hepatitis C and experimental fibrosis in rats [see comments].  Hepatology. 1999;  44 1730-1738
    PubMedGoogle Scholar
  • 34 Tahashi Y, Matsuzaki K, Date M. et al . Differential regulation of TGF-beta signal in hepatic stellate cells between acute and chronic rat liver injury.  Hepatology. 2002;  44 49-61
    PubMedGoogle Scholar
  • 35 Liu C, Gaca M D, Swenson E S. et al . Smads 2 and 3 are differentially activated by transforming growth factor-beta (TGF-beta) in quiescent and activated hepatic stellate cells. Constitutive nuclear localization of Smads in activated cells is TGF-beta-independent.  J Biol Chem. 2003;  44 11 721-11 728
    PubMedGoogle Scholar
  • 36 Furukawa F, Matsuzaki K, Mori S. et al . p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts.  Hepatology. 2003;  44 879-889
    PubMedGoogle Scholar
  • 37 Breitkopf K, Sawitza I, Westhoff J H. et al . Thrombospondin-1 acts as a strong promoter of TGF-beta effects via two distinct mechanisms in hepatic stellate cells.  Gut. 2005;  44 673-681
    PubMedGoogle Scholar
  • 38 Yoshida K, Matsuzaki K, Mori S. et al . Transforming growth factor-beta and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury.  Am J Pathol. 2005;  44 1029-1039
    PubMedGoogle Scholar
  • 39 Uemura M, Swenson E S, Gaca M D. et al . Smad2 and Smad3 play different roles in rat hepatic stellate cell function and alpha-smooth muscle actin organization.  Mol Biol Cell. 2005;  44 4214-4224
    PubMedGoogle Scholar
  • 40 Schnabl B, Kweon Y O, Frederick J P. et al . The role of Smad3 in mediating mouse hepatic stellate cell activation.  Hepatology. 2001;  44 89-100
    PubMedGoogle Scholar
  • 41 Lindert S, Wickert L, Sawitza I. et al . Transdifferentiation-dependent expression of alpha-SMA in hepatic stellate cells does not involve TGF-beta pathways leading to coinduction of collagen type I and thrombospondin-2.  Matrix Biol. 2005;  44 198-207
    PubMedGoogle Scholar
  • 42 Tsukada S, Westwick J K, Ikejima K. et al . SMAD and p38 MAPK signaling pathways independently regulate alpha1(I) collagen gene expression in unstimulated and transforming growth factor-beta-stimulated hepatic stellate cells.  J Biol Chem. 2005;  44 10 055-10 064
    PubMedGoogle Scholar
  • 43 Kobayashi M, Tanaka E, Sodeyama T. et al . The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses.  Hepatology. 1996;  44 695-699
    PubMedGoogle Scholar
  • 44 Yano M, Kumada H, Kage M. et al . The long-term pathological evolution of chronic hepatitis C.  Hepatology. 1996;  44 1334-1340
    PubMedGoogle Scholar
  • 45 Hiramatsu N, Hayashi N, Kasahara A. et al . Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha.  J Hepatol. 1995;  44 135-142
    PubMedGoogle Scholar
  • 46 Suou T, Hosho K, Kishimoto Y. et al . Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alfa.  Hepatology. 1995;  44 426-431
    PubMedGoogle Scholar
  • 47 Manabe N, Chevallier M, Chossegros P. et al . Interferon-alpha 2 b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation.  Hepatology. 1993;  44 1344-1349
    PubMedGoogle Scholar
  • 48 Duchatelle V, Marcellin P, Giostra E. et al . Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: quantitative assessment by a morphometric method.  J Hepatol. 1998;  44 20-28
    PubMedGoogle Scholar
  • 49 Sobesky R, Mathurin P, Charlotte F. et al . Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.  Gastroenterology. 1999;  44 378-386
    PubMedGoogle Scholar
  • 50 Bou-Gharios G, Garrett L A, Rossert J. et al . A potent far-upstream enhancer in the mouse pro alpha 2(I) collagen gene regulates expression of reporter genes in transgenic mice.  J Cell Biol. 1996;  44 1333-1344
    PubMedGoogle Scholar
  • 51 Greenwel P, Schwartz M, Rosas M. et al . Characterization of fat storing cell lines derived from normal and CCl4-cirrhotic livers.  Lab Invest. 1991;  44 644-653
    PubMedGoogle Scholar
  • 52 Inagaki Y, Nemoto T, Kushida M. et al . Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice.  Hepatology. 2003;  44 890-899
    PubMedGoogle Scholar
  • 53 Weng H, Wang B, Jia J. et al . Effect of interferon gamma on hepatic fibrosis in chronic hepatitis B virus infection: A randomized controlled study.  Clin Gastroenterol Hepatol. 2005;  44 819-828
    PubMedGoogle Scholar
  • 54 Dooley S, Said H M, Gressner A M, Floege J. et al . YB-1 is the crucial mediator of antifibrotic IFN-gamma effects.  J Biol Chem. 2005;  44
    PubMedGoogle Scholar
  • 55 Norman J T, Lindahl G E, Shakib K. et al . The Y-box binding protein YB-1 suppresses collagen alpha 1(I) gene transcription via an evolutionarily conserved regulatory element in the proximal promoter.  J Biol Chem. 2001;  44 29 880-29 890
    PubMedGoogle Scholar
  • 56 Sun W, Hou F, Panchenko M P. et al . A member of the Y-box protein family interacts with an upstream element in the alpha1(I) collagen gene.  Matrix Biol. 2001;  44 527-541
    PubMedGoogle Scholar
  • 57 Higashi K, Inagaki Y, Suzuki N. et al . Y-box-binding protein YB-1 mediates transcriptional repression of human alpha 2(I) collagen gene expression by interferon-gamma.  J Biol Chem. 2003;  44 5156-5162
    PubMedGoogle Scholar
  • 58 Higashi K, Inagaki Y, Fujimori K. et al . Interferon-gamma interferes with transforming growth factor-beta signaling through direct interaction of YB-1 with Smad3.  J Biol Chem. 2003;  44 43 470-43 479
    PubMedGoogle Scholar
  • 59 Inagaki Y, Kushida M, Higashi K. et al . Cell type-specific intervention of transforming growth factor beta/Smad signaling suppresses collagen gene expression and hepatic fibrosis in mice.  Gastroenterology. 2005;  44 259-268
    PubMedGoogle Scholar
  • 60 Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis.  Cell. 2004;  44 277-279
    PubMedGoogle Scholar
  • 61 Thiery J P. Epithelial-mesenchymal transitions in development and pathologies.  Curr Opin Cell Biol. 2003;  44 740-746
    PubMedGoogle Scholar
  • 62 Valdes F, Alvarez A M, Locascio A. et al . The epithelial mesenchymal transition confers resistance to the apoptotic effects of transforming growth factor Beta in fetal rat hepatocytes.  Mol Cancer Res. 2002;  44 68-78
    PubMedGoogle Scholar
  • 63 Amicone L, Spagnoli F M, Spath G. et al . Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes.  Embo J. 1997;  44 495-503
    PubMedGoogle Scholar
  • 64 Zhen Z, Giordano S, Longati P. et al . Structural and functional domains critical for constitutive activation of the HGF-receptor (Met).  Oncogene. 1994;  44 1691-1697
    PubMedGoogle Scholar
  • 65 Gotzmann J, Huber H, Thallinger C. et al . Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF-beta1 and Ha-Ras: steps towards invasiveness.  J Cell Sci. 2002;  44 1189-1202
    PubMedGoogle Scholar
  • 66 Mikula M, Fuchs E, Huber H. et al . Immortalized p19ARF null hepatocytes restore liver injury and generate hepatic progenitors after transplantation.  Hepatology. 2004;  44 628-634
    PubMedGoogle Scholar
  • 67 Fischer A N, Herrera B, Mikula M. et al . Integration of Ras subeffector signaling in TGF-beta mediated late stage hepatocarcinogenesis.  Carcinogenesis. 2005;  44 931-942
    PubMedGoogle Scholar
  • 68 Altomare D A, Testa J R. Perturbations of the AKT signaling pathway in human cancer.  Oncogene. 2005;  44 7455-7464
    PubMedGoogle Scholar
  • 69 Grille S J, Bellacosa A, Upson J. et al . The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines.  Cancer Res. 2003;  44 2172-2178
    PubMedGoogle Scholar
  • 70 Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3(kinase/AKT pathways.  Oncogene. 2005;  44 7443-7454
    PubMedGoogle Scholar
  • 71 Bakin A V, Tomlinson A K, Bhowmick N A. et al . Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration.  J Biol Chem. 2000;  44 36 803-36 810
    PubMedGoogle Scholar
  • 72 Murillo M M, del C astillo G, Sanchez A. et al . Involvement of EGF receptor and c-Src in the survival signals induced by TGF-beta1 in hepatocytes.  Oncogene. 2005;  44 4580-4587
    PubMedGoogle Scholar
  • 73 Gaunitz F, Deichsel D, Heise K. et al . An intronic silencer element is responsible for specific zonal expression of glutamine synthetase in the rat liver.  Hepatology. 2005;  44 1225-1232
    PubMedGoogle Scholar
  • 74 Hellerbrand C, Stefanovic B, Giordano F. et al . The role of TGF beta 1 in initiating hepatic stellate cell activation in vivo.  J Hepatol. 1999;  44 77-87
    PubMedGoogle Scholar
  • 75 Wells R G. The role of matrix stiffness in hepatic stellate cell activation and liver fibrosis.  J Clin Gastroenterol. 2005;  44 S158-161
    PubMedGoogle Scholar

Dr. Katja Breitkopf

Universitätsklinikum Mannheim, II. Medizinische Klinik, Gastroenterologie

Theodor-Kutzer-Ufer 1 - 3

68167 Mannheim

Email: katja.breitkopf@med.ma.uni-heidelberg.de

      >